Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	SEK 11.85	-5.58%	18,073
17/09/26	SEK 12.55	0.00%	46,541
16/09/26	SEK 12.55	-1.18%	2,390
15/09/26	SEK 12.70	-0.78%	319
14/09/26	SEK 12.80	-1.54%	110

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 02:00:00 19/09/26 am AEST			5-day change	1st Jan Change
11.85 ^SEK	-5.58%		-8.85%	-40.15%

17/09	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial	MT
22/08	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	83.65M 8.48M 7.4M 6.98M 6.34M 11.88M 814M 11.93M 32.28M 414M 31.86M 31.15M 1.33B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	83.65M 8.48M 7.4M 6.98M 6.34M 11.88M 814M 11.93M 32.28M 414M 31.86M 31.15M 1.33B	EV / Sales 2026 *	1.81x	EV / Sales 2027 *	2.53x
Free-Float	54.31%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ANNX	Delayed
Deutsche Boerse AG	Q910	Delayed

17/09	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial	MT
22/08	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/08	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
21/08	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection	CI
20/08	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
21/07	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
16/07	Calendar, Thursday, July 16	FW
23/06	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
15/06	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
10/06	Calendar Wednesday June 10	FW
09/06	Calendar Wednesday June 10	FW
21/05	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
11/05	Annexin receives German approval for ANXV clinical trial	RE

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news: Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

17/09	First patient treated with vanexin following anti-VEGF injection in the NEXUS study	AQ
10/09	Annexin Pharmaceuticals to Present at Investing in Life Science on September 22	AQ
21/08	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
20/08	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
21/07	Annexin updates on nine patients treated in NEXUS study	AQ

1 day	-5.58%
1 week	-8.85%
Current month	-11.24%
1 month	-10.90%
3 months	-2.47%
6 months	-18.28%
Current year	-40.15%

1 week	11.5	13.2
1 month	11.5	14.15
Current year	11.05	23.6
1 year	11.05	29.8
3 years	11.05	97.6
5 years	11.05	197.6
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	-5.58%	-8.85%	-57.68%	-83.81%	8.48M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+47.13%	+99.00%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	+2.12%	-5.86%	+161.58%	+329.34%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.24B
Average	-0.75%	+0.68%	+27.15%	+179.11%	27.48B
Weighted average by Cap.	-0.28%	+1.49%	+35.68%	+148.21%

	2026 *	2027 *
Net sales	46.3M 4.69M 4.09M 3.87M 3.51M 6.58M 450M 6.6M 17.87M 229M 17.63M 17.24M 737M	33.1M 3.36M 2.93M 2.76M 2.51M 4.7M 322M 4.72M 12.77M 164M 12.61M 12.33M 527M
Net income	-11.5M -1.17M -1.02M -960K -872K -1.63M -112M -1.64M -4.44M -56.88M -4.38M -4.28M -183M	-24.9M -2.52M -2.2M -2.08M -1.89M -3.54M -242M -3.55M -9.61M -123M -9.48M -9.27M -396M
Net Debt	-	-